Tigecycline Dosing Strategies in Critically Ill Liver-Impaired Patients.
Child–Pugh score
dose adjustment
population pharmacokinetics
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
03 Apr 2022
03 Apr 2022
Historique:
received:
21
03
2022
revised:
31
03
2022
accepted:
01
04
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
This study investigated tigecycline exposure in critically ill patients from a population pharmacokinetic perspective to support rational dosing in intensive care unit (ICU) patients with acute and chronic liver impairment. A clinical dataset of 39 patients served as the basis for the development of a population pharmacokinetic model. The typical tigecycline clearance was strongly reduced (8.6 L/h) as compared to other populations. Different models were developed based on liver and kidney function-related covariates. Monte Carlo simulations were used to guide dose adjustments with the most predictive covariates: Child-Pugh score, total bilirubin, and MELD score. The best performing covariate, guiding a dose reduction to 25 mg q12h, was Child-Pugh score C, whereas patients with Child-Pugh score A/B received the standard dose of 50 mg q12h. Of note, the obtained 24 h steady-state area under the concentration vs. time curve (AUC
Identifiants
pubmed: 35453230
pii: antibiotics11040479
doi: 10.3390/antibiotics11040479
pmc: PMC9028393
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Antimicrob Agents Chemother. 2008 Jan;52(1):204-10
pubmed: 17954694
Antimicrob Agents Chemother. 2013 Apr;57(4):1756-62
pubmed: 23357775
SAGE Open Med. 2020 Sep 18;8:2050312120958897
pubmed: 32999720
Crit Care. 2018 Dec 17;22(1):341
pubmed: 30558639
Eur J Clin Pharmacol. 2021 Feb;77(2):197-205
pubmed: 32975650
Int J Antimicrob Agents. 2013 May;41(5):463-7
pubmed: 23537581
Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S333-40
pubmed: 16080071
J Hepatol. 2012;56 Suppl 1:S1-12
pubmed: 22300459
Medicine (Baltimore). 2020 Mar;99(10):e19466
pubmed: 32150105
Ann Intensive Care. 2020 Aug 4;10(1):106
pubmed: 32754775
Front Microbiol. 2021 Jun 16;12:678165
pubmed: 34220762
Int J Infect Dis. 2014 Jan;18:62-7
pubmed: 24246741
Antimicrob Agents Chemother. 2000 Aug;44(8):2225-9
pubmed: 10898710
Comput Methods Programs Biomed. 2005 Sep;79(3):241-57
pubmed: 16023764
J Clin Pharmacol. 2007 Jun;47(6):727-37
pubmed: 17519399
Am J Health Syst Pharm. 2007 Apr 1;64(7):690, 692-3
pubmed: 17384352
J Pharmacokinet Pharmacodyn. 2004 Apr;31(2):109-34
pubmed: 15379381
J Hepatol. 2005;42 Suppl(1):S100-7
pubmed: 15777564
Antimicrob Agents Chemother. 2012 Jan;56(1):130-6
pubmed: 21968360
Antimicrob Agents Chemother. 2007 Jun;51(6):1939-45
pubmed: 17353238
Antimicrob Agents Chemother. 2018 Mar 27;62(4):
pubmed: 29358291
Infect Dis (Lond). 2018 Jul;50(7):507-513
pubmed: 29316830
J Pharmacokinet Pharmacodyn. 2020 Jun;47(3):219-228
pubmed: 32248328
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
J Surg Res. 2015 Jan;193(1):184-9
pubmed: 25150081
Int J Antimicrob Agents. 2017 Oct;50(4):557-563
pubmed: 28711678
Ann Intensive Care. 2020 Jul 13;10(1):94
pubmed: 32661791
Adv Ther. 2020 Mar;37(3):1049-1064
pubmed: 32006240
Intensive Care Med. 2014 Jul;40(7):988-97
pubmed: 24871500
Clin Pharmacokinet. 1997 Jan;32(1):30-57
pubmed: 9012555
J Clin Pharmacol. 2012 Sep;52(9):1379-87
pubmed: 21953572
Crit Care. 2014 May 05;18(3):R90
pubmed: 24887101
J Chemother. 2020 Dec;32(8):420-428
pubmed: 32757849
J Clin Pharmacol. 2011 Jan;51(1):93-101
pubmed: 20308689
J Antimicrob Chemother. 2020 Dec 1;75(12):3619-3624
pubmed: 32887993
Antimicrob Agents Chemother. 2006 Nov;50(11):3701-7
pubmed: 16940069